Friday, January 6, 2023 Daily Archives

MaxCyte signs electroporation deal with Catamaran

Catamaran Bio will have non-exclusive clinical and commercial rights to use MaxCyte’s Flow Electroporation technology and ExPERT platform. MaxCyte has signed a strategic platform licence (SPL) with Catamaran, a company focused on developing off-the-shelf chimeric antigen receptor natural killer (CAR-NK) cell therapies used to treat a wide range of cancers, particularly solid tumors. While financial details of this deal remain undisclosed, MaxCyte has confirmed it will receive platform licensing fees and program-related revenue under the terms of the agreement. “The…

Sartorius and RoosterBio extend stem cell production partnership

The extended collaboration sees Sartorius and RoosterBio aim to commercialize exosome production and purification processes using various technologies.  The partnership between Sartorius and RoosterBio began almost two years ago. The firms teamed up to find ways of scaling-up production of stem cell-based regenerative therapies and combined Rooster’s human mesenchymal stem/stromal cell (hMSC) working cell banks and media systems with Sartorius’ single-use manufacturing tech, process control software and analysis tools. Now, both parties say the extended partnership looks to “take a…